Reducing economic burden and improving quality of life in pulmonary arterial hypertension

Burgoyne, Douglas

doi:10.37765/ajmc.2021.88611

Cited by 11 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“… 12 , 36 , 37 Thus, the clinical burden of disease in PAH could be alleviated if patients had timely access to all available PAH treatment classes, including combination therapies targeting the nitric oxide, endothelin, and prostacyclin pathways. 10 , 13 , 35 …”

Section: Discussionmentioning

confidence: 99%

“…19 In light of these previously reported trends, along with the substantial cost impact observed in the present study, there is a continued need for PAH management strategies that could address this growing burden of disease. 35 Contemporary prescribing practices, such as the increased use of early combination therapy, may help to prevent further increases in the HRU burden among patients with CTD + PAH despite higher pharmacy costs. This treatment strategy is also supported by prior analyses of clinical trial data and evidence from retrospective claimsbased studies.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD)

et al. 2023

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is commonly associated with connective tissue disorders (CTDs). This study provides a contemporary assessment of the economic burden of CTD + PAH and PAH in the United States. Eligible adult patients identified from Optum's deidentified Clinformatics® Data Mart Database (10/01/2015‐09/30/2021) were classified into mutually exclusive cohorts based on recorded diagnoses: (1) CTD + PAH, (2) PAH, (3) CTD, (4) control without CTD/PAH. The index date was a randomly selected diagnosis date for PAH (CTD + PAH, PAH cohorts) or CTD (CTD cohort), or a random date (control cohort). Entropy balancing was used to balance characteristics across cohorts. Healthcare costs and healthcare resource utilization (HRU) per patient per month (PPPM) were assessed for ≤12 months postindex and compared among balanced cohorts. A total of 552,900 patients were included (CTD + PAH: n = 1876; PAH: n = 8177; CTD: n = 209,156; control: n = 333,691). Average total all‐cause costs were higher for CTD + PAH than PAH cohort ($16,854 vs. $15,686 PPPM; p = 0.02); both cohorts incurred higher costs than CTD and control cohorts ($4476 and $2170 PPPM; all p < 0.001). Average HRU PPPM was similar between CTD + PAH and PAH cohorts (inpatient stay: 0.15 vs. 0.15, outpatient visits: 4.23 vs. 4.11; all p > 0.05), while CTD and control cohorts incurred less HRU (inpatient stay: 0.07 and 0.03, outpatient visits: 2.67 and 1.69; all p < 0.001). CTD + PAH and PAH are associated with a substantial economic burden. The incremental burden attributable to PAH versus the general population and patients with CTD without PAH highlights significant unmet needs among PAH patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD)

et al. 2023

View full text Add to dashboard Cite

show abstract

“…LMICs should increase the gross economic expenditure on research and development to increase understanding to deploy new technology to reduce the burgeoning epidemic of hypertension [ 17 ]. It is important to involve patients in the clinical decision-making process and access to multi-disciplinary care [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Socioeconomic Macro-Level Determinants of Hypertension: Ecological Analysis of 138 Low- and Middle-Income Countries

Abba

Nduka

Anjorin

et al. 2023

JCDD

View full text Add to dashboard Cite

Aim: To assess the relative importance of major socioeconomic determinants of population health on the burden of hypertension in Low-and-Middle-Income Countries (LMICs). Methods: Country-level data from 138 countries based on World Development Indicators 2020 were used for correlation and linear regression analyses of eight socioeconomic predictors of hypertension: current health expenditure, domestic general government health expenditure per capita, GDP per capita, adult literacy rate, unemployment rate, urban population, multidimensional poverty index, and total population. Results: The median prevalence of age-standardised hypertension was 25.8% across the 138 countries, ranging from 13.7% in Peru to 33.4% in Niger. For every 10% increase in the unemployment rate, the prevalence of hypertension increased by 2.70%. For every 10% increase in the percentage of people living in urban areas, hypertension was reduced by 0.63%. Conclusions: The findings revealed that countries with high GDP, more investment in health and an improved multidimensional poverty index have a lower prevalence of hypertension.

show abstract

“…Once the diagnosis of PAH is made, the direct cost per patient per month is 4 to 5 times higher than matched controls by age, sex, geographical area, and annual income. 14 Clinical trial and meta‐analysis data support early initiation of combination therapy with a phosphodiesterase type 5 inhibitor (PDE5) and an endothelin receptor antagonist (ERA), resulting in a significant reduction in morbidity and mortality. 15 , 16 As the disease progresses, so does the pharmacy cost because of the increased number and complexity of medications such as prostanoids (oral, inhaled, or parenteral) and soluble guanylate cyclase stimulators.…”

mentioning

confidence: 99%

Where's the Easy Button? The Many Barriers to Care for Patients With Pulmonary Arterial Hypertension

Cantres‐Fonseca

Kennedy

2022

JAHA

View full text Add to dashboard Cite

Reducing economic burden and improving quality of life in pulmonary arterial hypertension

Cited by 11 publications

References 0 publications

Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD)

Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD)

Socioeconomic Macro-Level Determinants of Hypertension: Ecological Analysis of 138 Low- and Middle-Income Countries

Where's the Easy Button? The Many Barriers to Care for Patients With Pulmonary Arterial Hypertension

Contact Info

Product

Resources

About